ReviewCurrent opinion in microbiology2011
CRISPR-based adaptive immune systems.
Review in Current opinion in microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 225 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
225 citing papers in PubMed, 1 synthesis or guideline pooled it, 435 citations in OpenAlex.
- Using Clustered Regularly Interspaced Short Palindromic Repeats gene editing to induce permanent expression of fetal hemoglobin in β-thalassemia and sickle cell disease: A comparative meta-analysis.Frontiers in medicine · 2022Pooled it
- Edible Vaccines: A Paradigm Shift in Vaccine Delivery and Global Health Solutions.Current drug discovery technologies · 2026Review
- Evolutionary dynamics of type VI secretion systems in fruit fly-associatedFrontiers in microbiology · 2026Article
- Advances in plant metabolic engineering through synthetic biology.Frontiers in plant science · 2026Review
- The First CRISPR-Based Therapeutic (SL_1.52) for African Swine Fever Is Effective in Swine.Viruses · 2025Article
- Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems.Journal of nanobiotechnology · 2025Review
- Novel application of ribonucleoprotein-mediated CRISPR-Cas9 gene editing in plant pathogenic oomycete species.Microbiology spectrum · 2025Article
- SspA is a transcriptional regulator of CRISPR adaptation in E. coli.Nucleic acids research · 2025Article
- Synthetic biology meets Aspergillus: engineering strategies for next-generation organic acid production.World journal of microbiology & biotechnology · 2025Review
- CRISPR/Cas-Based Nanobiosensor Using Plasmonic Nanomaterials to Detect Disease Biomarkers.Biochip journal · 2025Review
- Application of CRISPR/Cas gene editing for infectious disease control in poultry.Open life sciences · 2025Review
- Digital CRISPR-Powered Biosensor Concept without Target Amplification Using Single-Impact Electrochemistry.ACS sensors · 2024Article
- Characteristics and immune functions of the endogenous CRISPR-Cas systems in myxobacteria.mSystems · 2024Article
- Mechanisms used for cDNA synthesis and site-specific integration of RNA into DNA genomes by a reverse transcriptase-Cas1 fusion protein.Science advances · 2024Article
- Resensitizing tigecycline- and colistin-resistantMicrobiology spectrum · 2024Article
- Breaking genetic shackles: The advance of base editing in genetic disorder treatment.Frontiers in pharmacology · 2024Review
- Workflow for Performing Genetic Manipulation in Human Trophoblast Stem Cells Using CRISPR/Cas9 Technology.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Innate and germline immune memory: specificity and heritability of the ancient immune mechanisms for adaptation and survival.Frontiers in immunology · 2024Review
- Manipulating the Destiny of Wild Populations Using CRISPR.Annual review of genetics · 2023Review
- Qualitative and Quantitative Detection of CRISPR-AssociatedFoods (Basel, Switzerland) · 2023Article
165 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
CRISPR-Cas systems are recently discovered, RNA-based immune systems that control invasions of viruses and plasmids in archaea and bacteria. Prokaryotes with CRISPR-Cas immune systems capture short invader sequences within the CRISPR loci in their genomes, and small RNAs produced from the CRISPR loci (CRISPR (cr)RNAs) guide Cas proteins to recognize and degrade (or otherwise silence) the invading nucleic acids. There are multiple variations of the pathway found among prokaryotes, each mediated by largely distinct components and mechanisms that we are only beginning to delineate. Here we will review our current understanding of the remarkable CRISPR-Cas pathways with particular attention to studies relevant to systems found in the archaea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.